NCT04903210

Nicotinamide Mononucleotide in Hypertensive Patients

Status unknown Phase 4 Last updated 1 February 2022

What this trial tests

Phase 4 trial testing Nicotinamide mononucleotide supplied as 400mg capsule in Hypertension in 20 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
20 June 2022

31 July 2022

Quick facts

Lead sponsor	First Affiliated Hospital, Sun Yat-Sen University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 June 2021
Primary completion	20 June 2022
Estimated completion	31 July 2022
Sites	1 location across China

Drugs / interventions tested

• Nicotinamide mononucleotide supplied as 400mg capsule
• Lifestyle modification

Conditions studied

• Hypertension — all drugs for Hypertension →

Sponsor

First Affiliated Hospital, Sun Yat-Sen University

Who can join

Adults 18 to 65, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiovascular and cerebrovascular diseases are most terrible killers endangering the health of Chinese residents, and hypertension is the most important risk factor. Hypertension related vascular function and structural damage are the common pathological basis and initiation of cardiovascular and cerebrovascular disease. Therefore, reducing blood pressure and delaying or reversing vascular injury is an effective way to treat hypertension and prevent cardiovascular disease. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme of many kinds of dehydrogenases in the body, and is an essential molecule in the basic process of life support. The latest research found that with the growth of age, the level of NAD+ is decreasing, and increasing the content of NAD+ can prolong the life of multiple species including human. NMN (β - nicotinamide mononucleotide) is a natural NAD+ precursor in cells. Recent clinical trials found that NMN supplementation can effectively improve the level of NAD+ in cells, delay aging, improve the metabolic process of cells without adverse reactions. However, the effect of NMN supplementation on reducing blood pressure and protecting vascular endothelial function has not been reported. Therefore, this study aims to focus on hypertension, a major chronic disease, and to observe the effects of NMN supplementation on vascular function and blood pressure in patients with hypertension, so as to provide a new treatment strategy for hypertension and associated vascular injury.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Epigenetic regulation of aging: implications for interventions of aging and diseases.
   Wang K, Liu H, Hu Q, Wang L, et al · · 2022 · cited 406× · PMID 36336680 · DOI 10.1038/s41392-022-01211-8
2. NAD⁺ in COVID-19 and viral infections.
   Zheng M, Schultz MB, Sinclair DA. · · 2022 · cited 46× · PMID 35221228 · DOI 10.1016/j.it.2022.02.001
3. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health.
   Alegre GFS, Pastore GM. · · 2023 · cited 44× · PMID 37273100 · DOI 10.1007/s13668-023-00475-y
4. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults.
   Huang H. · · 2022 · cited 38× · PMID 35821806 · DOI 10.3389/fragi.2022.851698
5. NAD⁺ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension.
   Qiu Y, Xu S, Chen X, Wu X, et al · · 2023 · cited 35× · PMID 37718359 · DOI 10.1038/s41392-023-01577-3
6. Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan.
   Sharma A, Chabloz S, Lapides RA, Roider E, et al · · 2023 · cited 35× · PMID 36678315 · DOI 10.3390/nu15020445
7. Therapeutic Potential of Emerging NAD+-Increasing Strategies for Cardiovascular Diseases.
   Rotllan N, Camacho M, Tondo M, Diarte-Añazco EMG, et al · · 2021 · cited 25× · PMID 34943043 · DOI 10.3390/antiox10121939
8. Chronic HIV Infection and Aging: Application of a Geroscience-Guided Approach.
   Masters MC, Landay AL, Robbins PD, Tchkonia T, et al · · 2022 · cited 21× · PMID 35015744 · DOI 10.1097/qai.0000000000002858